In this article, we will discuss Binimetinib (Dosage Overview). So, let’s get started.
Binimetinib is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Confirm the presence of a BRAF V600E or V600K mutation in tumor specimens prior to initiating binimetinib.
The recommended dosage of binimetinib is 45 mg orally taken twice daily, approximately 12 hours apart, in combination with encorafenib until disease progression or unacceptable toxicity. Do not take a missed dose of binimetinib within 6 hours of the next dose of binimetinib. Do not take an additional dose if vomiting occurs after binimetinib administration but continue with the next scheduled dose.